Global Gastrointestinal Partnering 2014-2021: Deal trends, players and financials


The Global Gastrointestinal Partnering 2014-2021: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the gastrointestinal partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
October 2021
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

Global Gastrointestinal Partnering 2014 to 2021 provides the full collection of Gastrointestinal disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.


  • Trends in Gastrointestinal partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Gastrointestinal partnering agreement structure
  • Gastrointestinal partnering contract documents
  • Top Gastrointestinal deals by value
  • Most active Gastrointestinal dealmakers


Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.


The report takes readers through the comprehensive Gastrointestinal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gastrointestinal deals.


The report presents financial deal terms values for Gastrointestinal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.


The initial chapters of this report provide an orientation of Gastrointestinal dealmaking trends.


Chapter 1 provides an introduction to the report.


Chapter 2 provides an overview of the trends in Gastrointestinal dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.


Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.


Chapter 4 provides a review of the leading Gastrointestinal deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Gastrointestinal dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.


Chapter 5 provides comprehensive access to Gastrointestinal deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.


Chapter 6 provides a comprehensive directory of all Gastrointestinal partnering deals by specific Gastrointestinal target announced since 2014. The chapter is organized by specific Gastrointestinal therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


In addition, a comprehensive appendix is provided with each report of all Gastrointestinal partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The report also includes numerous tables and figures that illustrate the trends and activities in Gastrointestinal partnering and dealmaking since 2014.  


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gastrointestinal technologies and products.


Report scope


Global Gastrointestinal Partnering 2014 to 2021 is intended to provide the reader with an in-depth understanding and access to Gastrointestinal trends and structure of deals entered into by leading companies worldwide.


Global Gastrointestinal Partnering 2014 to 2021 includes:


  • Trends in Gastrointestinal dealmaking in the biopharma industry since 2014
  • Analysis of Gastrointestinal deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Gastrointestinal deal contract documents
  • Comprehensive access to Gastrointestinal deal records
  • The leading Gastrointestinal deals by value since 2014
  • Most active Gastrointestinal dealmakers since 2014


The report includes deals for the following indications: Appendicitis, Celiac disease, Esophageal reflux, Esophagitis, Gastritis, Gastroenteritis, Hemorrhoids (haemorrhoids), Hernia, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Irritable bowel syndrome, Malabsorption, Malnutrition, Pancreatitis, Peptic ulce, Gastric ulcer, Duodenal ulcer, Abdominal pain, Ascites, Bowel movement, Constipation, Diarrhea, Jaundice, Vomitting, plus other gastrointestinal indications.


In Global Gastrointestinal Partnering 2014 to 2021, available deals and contracts are listed by:


  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 


The Global Gastrointestinal Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for gastrointestinal deals. Analyzing actual contract agreements allows assessment of the following:


  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Gastrointestinal Partnering 2014 to 2021 provides the reader with the following key benefits:


  • In-depth understanding of Gastrointestinal deal trends since 2014
  • Access Gastrointestinal deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Gastrointestinal partner companies
  • Comprehensive access to links to actual Gastrointestinal deals entered into by the world’s biopharma companies
  • Indepth review of Gastrointestinal deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Gastrointestinal opportunities
  • Uncover companies actively partnering Gastrointestinal opportunities

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in Gastrointestinal dealmaking


2.1. Introduction

2.2. Gastrointestinal partnering over the years    

2.3. Gastrointestinal partnering by deal type

2.4. Gastrointestinal partnering by industry sector

2.5. Gastrointestinal partnering by stage of development

2.6. Gastrointestinal partnering by technology type

2.7. Gastrointestinal partnering by therapeutic indication


Chapter 3 –Financial deal terms for Gastrointestinal partnering


3.1. Introduction

3.2. Disclosed financials terms for Gastrointestinal partnering

3.3. Gastrointestinal partnering headline values

3.4. Gastrointestinal deal upfront payments

3.5. Gastrointestinal deal milestone payments

3.6. Gastrointestinal royalty rates


Chapter 4 – Leading Gastrointestinal deals and dealmakers


4.1. Introduction

4.2. Most active in Gastrointestinal partnering

4.3. List of most active dealmakers in Gastrointestinal   

4.4. Top Gastrointestinal deals by value


Chapter 5 – Gastrointestinal contract document directory


5.1. Introduction

5.2. Gastrointestinal partnering deals where contract document available


Chapter 6 – Gastrointestinal dealmaking by therapeutic target


6.1. Introduction

6.2. Deals by Gastrointestinal therapeutic target




Appendix 1 – Directory of Gastrointestinal deals by company A-Z since 2014

Appendix 2 – Directory of Gastrointestinal deals by deal type since 2014

Appendix 3 – Directory of Gastrointestinal deals by stage of development since 2014

Appendix 4 – Directory of Gastrointestinal deals by technology type since 2014

Further reading on dealmaking

Deal type definitions


About Wildwood Ventures


Current Partnering

Current Agreements

Recent report titles from CurrentPartnering


Table of figures


Figure 1: Gastrointestinal partnering since 2014

Figure 2: Gastrointestinal partnering by deal type since 2014

Figure 3: Gastrointestinal partnering by industry sector since 2014

Figure 4: Gastrointestinal partnering by stage of development since 2014

Figure 5: Gastrointestinal partnering by technology type since 2014

Figure 6: Gastrointestinal partnering by indication since 2014

Figure 7: Gastrointestinal deals with a headline value

Figure 8: Gastrointestinal deals with upfront payment values

Figure 9: Gastrointestinal deals with milestone payment

Figure 10: Gastrointestinal deals with royalty rates

Figure 11: Active Gastrointestinal dealmaking activity since 2014

Figure 12: Top Gastrointestinal deals by value since 2014

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license


A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

4D Pharma, 23andMe, AB-Biotics, AB Analitica, Abbvie, Ab E Discovery, Adacyte Therapeutics, AdaptVac, ADL Bionatur Solutions, Advanced Medical German Company of Kuwait, Aerpio Pharmaceuticals, Aevi Genomic Medicine, AIDS Clinical Trials Group, Akebia Therapeutics, Akeso Biopharma, Akkadeas Pharma, Alab, Alba Therapeutics, Albireo, Alfasigma, Alimentary Health, Alivio Therapeutics, Allen Institute for Brain Science, Allergan, Alma Bio Therapeutics, Almirall, Alnylam Pharmaceuticals, Altos Group, Alvine Pharmaceuticals, Alvit LCS Pharma, Alvotech, Amarex Clinical Research, Ambu, Americas Hernia Society Quality Collaborative, Amgen, Amneal Pharmaceuticals, Amunix, Anatara Lifesciences, Angelini Pharma, ANI Pharmaceuticals, Anokion, Antibe Therapeutics, Apharm, Applied Molecular Transport, Arcadia Consumer Healthcare, Arc Medical Design, Ardelyx, Ariel Precision Medicine, Aries Pharmaceuticals, Artizan Biosciences, Asana Medical, Ascension Health Ventures, AscentX Medical, Asklepion Pharmaceuticals, Assembly Biosciences, Astellas Pharma, AstraZeneca, Asymchem Laboratories, Atlantic Healthcare, Atnahs Pharma, Aurobindo Pharma, Australasian Gastro Intestinal Research Foundation, Aziyo Biologics, AzurRx BioPharma, Back-A-Line, Bausch Health Companies, Baxalta, Baxter International, Bayer Healthcare, Bazelet, B Braun, BC Children's Hospital, BDD Pharma, Beacon Discovery, Bestbion, Best Choice, BHR Pharma, Bill and Melinda Gates Foundation, Bio-Me, Bio-Rad Laboratories, BioClinica, Biocodex Microbiota Foundation, BioDelivery Sciences, BioFire Diagnostics, Biofortis, Biogen, BIOgenetiX, Biohaven Pharmaceutical Holding, Biohit, Biomecite Diagnostics, Biomedical Advanced Research and Development Authority, Biomedica Medizinprodukte, BioMed X Innovation Center, Biomerica, BiomX, Bioportugal Quimica Farmaceutica, BioRap Technologies, Biostage, BioStorage Technologies, BioSurfaces, Boehringer Ingelheim, Boston Pharmaceuticals, Bpifrance, Bridge Biotherapeutics, Bristol-Myers Squibb, Broad Institute, Buchang Pharmaceutical, Calypso Biotech, Camargo Pharmaceutical Services, Cambridge Clinical Laboratories, Cancer Prevention Pharmaceuticals, CannaKids, Cantel Medical, CapsoVision, Capsulomics, Captor Therapeutics, Cara Care, Carbiotix, Case Western Reserve University, Casper Pharma, CB2 Therapeutics, CDx Diagnostics, Cedars-Sinai Medical Center, Celgene, Celiac Disease Foundation, Celimmune, Cell Therapy Catapult, Celltrion, Celsius Therapeutics, Censis Technologies, Centre Hospitalier Régional Universitaire (CHRU) de Lille, Cerevance, Cernostics, Certara, Charles River Laboratories, Cheplapharm Arzneimittel, Children's Hospital of Philadelphia, Chinese University of Hong Kong, CHU Sainte-Justine, Cilag AG, Cincinnati Children’s Hospital Medical Center, Cipher Pharmaceuticals, Cipla, CIRCA Scientific, CJ Corp, Cleveland Clinic, Clinigen, Codexis, Coherus Biosciences, Commonwealth Laboratories, Complix, Concordia Healthcare, Concordia Pharmaceuticals, Connecticut Children’s Medical Center, ConvaTec, Cook Biotech, Cook Medical, Cornell University, Cosmo Pharmaceuticals, COUR Pharmaceutical, Creapharm, CRH Medical, Crohn's and Colitis Foundation of America, CRS Bio, Curant Health, CURE Pharmaceutical, Cyclerion Therapeutics, Cytocom, Daewoong Pharmaceutical, Daiichi Sankyo, Danish Innovation Fund, DBV Technologies, Debiopharm, Deciphex, Delphi Genetics, Department of Defense, Dermira, Diagnoplex, Diagnostic International Distribution, Diagnovus, Diversigen, Dongkook Pharmaceutical, Dr. Falk Pharma, Dr. Reddy's Laboratories, EA Pharma, ECM Therapeutics, Eisai, Eisai Inc, Elanco, Eli Lilly, Endo-Therapeutics, Endo International, EndoLogic, enGene, Engitix, Entellus Medical, Entera Health, Enterome Bioscience, Entrinsic Health Solutions, Epirus Biopharmaceuticals, EtectRx, Eunice Kennedy Shriver Institute of Child Health and Human Development, Eurobio, European Union, Eversana, Evoke Pharma, Evolve BioSystems, Evommune, Evotec, Ewopharma, Exact Sciences, ExeGi Pharma, Faes Farma, Ferring Pharmaceuticals, Fiagon, Finch Therapeutics, First Wave Bio, Food and Drug Administration (FDA), Food Marble Digestive Health, Fosun Pharmaceutical, Foundation for Celiac Disease Outcome Measures, Frazier Healthcare Ventures, French National Institute for Agricultural Research, Fresenius Kabi Pharmaceuticals, Fresenius Medical Care, FSC Laboratories, FSC Pediatrics, FSD Pharma, Fujifilm, Fujifilm Kyowa Kirin Biologics, G-Tech Medical, Galapagos, Galena Biopharma, Gemelli Biotech, Genentech, General Automation Lab Technologies, Genetic Analysis, Genten Therapeutics, Georgia State University, Gilead Sciences, GI Partners of Illinois, Giraffes Pharmaceutical, GI Reviewers, GlaxoSmithKline, Glenmark Pharmaceuticals, Global Centers for Therapeutic Innovation, Gossamer Bio, Great Belief International, Great Ormond Street Hospital (GOSH), Grunenthal, Grupo Ferrer, Hadasit Bioholdings, Hadasit Medical Research Services and Development, Haisco Pharmaceutical, Harvard Apparatus Regenerative Technology, Harvest Capital Strategies, Hawaii Medical, Healthcare Royalty Partners, HealthTrust, Helsinn Healthcare, Henry Schein, HiFiBio, Highland Therapeutics, Hollister-Stier Labs, Holobiome, Horizon 2020, Hoth Therapeutics, Humabs BioMed, Icahn School of Medicine at Mount Sinai, Idera Pharmaceuticals, IMIDomics, Immune Pharmaceuticals, Immune Therapeutics, ImmuNext, Immunic, ImmunogenX, Impax Laboratories, Imperial College London, Inception Sciences, Indegene Lifesystems, InDex Pharmaceuticals, Indiana Biosciences Research Institute, Infirst HEALTHCARE, INNOVAMEDICA, Innovate Biopharmaceuticals, Innovation Pharmaceuticals, InQpharm, Insightra Medical, Institut Gustave Roussy, Instituto de Ciencias Farmaceuticas, International Centre for Diarrhoeal Disease Research, Interscope, Intract Pharma, Intralytix, Intrexon, IntroMedic, Ionis Pharmaceuticals, Ipsen, Ironwood Pharmaceuticals, ISA Scientific, ISOThrive, Iterative Scopes, Jaguar Health, Jamieson, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Janssen Sciences, Jitsubo, Johns Hopkins University, Johnson & Johnson Consumer Companies, Johnson & Johnson Innovation, JSR, Juntendo University, Juventas Therapeutics, Kanyos, Karl Storz, Karolinska Institute, Karo Pharma, Keio Gijuku University, Kennedy Trust For Rheumatology Research, Kenneth Rainin Foundation (KRF), KineMed, Kings College London, Knight Therapeutics, Korea Pharma, Kwang Dong Pharmaceutical, Kyowa Hakko Kirin, Laboratories Acbel, Laboratorio Daudt, Laboratorios Bago, Lamassu Pharma, Lead Pharma, Leona M and Harry B Helmsley Charitable Trust, LEO Pharma, Les Laboratoires Servier, Lipid Therapeutics, LiveLeaf, LMU University Hospital Munich, LNC, Lonza, Lucid Diagnostics, Luminex, Lycera, Magellan Health Services, Magnet Sales and Manufacturing, Marinomed Biotechnologie, Massachusetts General Hospital, Mauna Kea Technologies, Mayo Clinic, McMaster University, McNeil Consumer Pharmaceuticals, Medgenics, MediBeacon, Medical University of Graz, Medical University of Vienna, MediGene, Medigus, MedImmune, Memorial Hermann Health System, Merit Medical Systems, Mesoblast, Metabiomics, Metagenics, Micro-Tech Endoscopy, Microbiotica, Microline Surgical, Midatech, Mission Cure, MiTest Health, Mitsubishi Tanabe Pharma, Mobidiag, Molteni Farmaceutici, Momenta Pharmaceuticals, Monash University, Morphic Therapeutic, Mor Research Applications, Motus GI Medical Technologies, Mundipharma, MyBiotics Pharma, Mylan Laboratories, Mylan Pharmaceuticals, Naia Pharma, Nanjing Micro-Tech, National Heart, Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Naval Medical Research Center, Nektar Therapeutics, Neoteryx, Nestle Health Science, NeuTec Pharma, Nexus Medical, Ninepoint Medical, Nodality, Nogra Pharma, Norgine, Northwestern University, North Zealand University Hospital, NovaMedica, Novartis, Novartis Institute for Tropical Diseases, Noventure, Novigenix, NovImmune, Novo Nordisk, NuBiyota, Numab, NuMedii, Numerate, Nutriband, Nutricion, NYU Langone Medical Center, Olympus, Olympus Medical Systems, Omega Pharma, Onegevity, Origin Biosciences, OSE Immunotherapeutics, Otsuka, Otsuka America Pharmaceutical, Owlstone Medical, PACA Inovation, Palobiofarma, Panaxia, PanTheryx, Paragon Bioservices, ParaPRO, Parexel, Parexel Biotech, Parvus Therapeutics, Path BioAnalytics, Patheon, PAVmed, PEAR Therapeutics, Pendopharm, Penn State Microbiome Center, Pentax, Perelman School of Medicine, PerkinElmer, Perrigo, Pfizer, PharmaCare Management, PharmaSwiss, Phathom Pharmaceuticals, Pierre Fabre, PlantEXT, Pliant Therapeutics, Polpharma, Portal Instruments, PPD, Prana Biotechnology, PredictImmune, Premier Inc, Prescient Medical, Probi, ProciseDx, Progressive Medical International, Progressive Spinal Technologies, Prometheus Laboratories, Pronutria, Protagonist Therapeutics, Provention Bio, Proxy Biomedical, Purdue Pharma, PureTech Health, PvP Biologics, Qualicaps, Qu Biologics, Queen Mary University of London, Quest Diagnostics, Quotient Clinical, R-Tech Ueno, Rafa Pharmaceuticals, ReadSense Genomic Center, Rebiotix, Reckitt Benckiser, Recordati, RedHill Biopharma, Regentys, Renexxion, Repligen, ReproCell, ResearchMatch, Retrophin, Revive Pharmaceuticals, Rising Pharmaceuticals, Ritter Pharmaceuticals, Roche, Romark Laboratories, Royal Free Hospital, Royalty Pharma, Salix Pharmaceuticals, Samsung Bioepis, Sandoz, Sanofi, Saphena Medical, SciCann Therapeutics, Scipher Medicine, Scripps Research Institute, Second Genome, Seed Mena, Selexis, Sequana Medical, Seres Therapeutics, Shandong Luoxin Pharma, Shionogi, Shire Pharmaceuticals, Signum Surgical, Simulations Plus, Sinovant Sciences, Sloan Pharma, Smart Medical Systems, Soligenix, SomaLogic, SonarMD, Sosei, Sosei Heptares, SpectraScience, Starton Therapeutics, Strand Life Sciences, Stratis Medical, Structural Genomics Consortium, Sucampo Pharmaceuticals, Sutter Health, Swedish Orphan Biovitrum, Swixx Biopharma, Symbiotix Biotherapies, Synergy Pharmaceuticals, Synlab, Synlogic, Synthetic Biologics, Taewoong Medical, Takeda Pharmaceutical, TARGET PharmaSolutions, Telcon RF Pharmaceuticals, Teligent, Tetra Bio-Pharma, Texas A&M Health Science Center, The Cell and Gene Therapy Unit, The Crohn's and Colitis Foundation of Canada, The HUB Foundation, Theradiag, Theranostica, Theravance, Theravance Biopharma, The Vancouver Island Health Authority, Thiel Foundation, Thorne Research, Tianyin Pharmaceutical, TiGenix, Tillotts Pharma, Tissium, Tiziana Life Sciences, TransEnterix, Trizell, Twist Bioscience, TxCell, UCB, Unilabs, UniQuest, United Digestive, Universite catholique de Louvain, University College Cork, University College London, University of Adelaide, University of Birmingham, University of British Columbia, University of Calgary, University of California, San Diego, University of California Los Angeles, University of California San Francisco, University of Manitoba, University of Maryland Ventures, University of Massachusetts, University of North Carolina, University of Oslo, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Sherbrooke, University of Tokyo, University of Washington, University of Windsor, Utrecht University, Valbiotis, Vcell Healthcare, V ClinBio, Vedanta Biosciences, Vedco, Verily, Vertex Pharmaceuticals, Via Surgical, Vinnova, VIPUN Medical, Virginia Catalyst, Virios Therapeutics, Vital Food Processors, Vital Therapies, Vivante Health, Vivelix Pharmaceuticals, Vizient, Washington University in St Louis, Weill Cornell Medical College, Wockhardt, WuXi Biologics, Xoma, Yale University, Yissum Research Development, Zealand Pharma

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.